SOM Biotech

Executive Summary

SOM Biotech is a late clinical-stage biopharmaceutical company based in Barcelona, Spain, founded in 2010. The company leverages its proprietary AI-powered drug discovery platform, SOMaiPRO®, to identify and develop small molecule therapies for rare central nervous system (CNS) disorders. Its lead asset, SOM4401, is ready to enter Phase 3 clinical trials for Huntington's disease, a devastating neurodegenerative condition with no disease-modifying treatments. The company has a pipeline of additional candidates targeting other rare CNS indications, all discovered through its AI platform. SOM Biotech's approach combines computational biology with medicinal chemistry to accelerate drug development and reduce costs, positioning it as a potential leader in precision CNS therapeutics. The company is privately held and has not disclosed total funding or valuation, but its late-stage asset and focus on high-unmet-need areas suggest significant upside potential.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Trial Initiation for SOM4401 in Huntington's Disease60% success
• TBDPotential Series C Financing or Partnership Announcement70% success
• Q4 2026Interim Phase 2 Data Readout for Pipeline Candidate in Other CNS Indication50% success